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Abstract
Genome-wide association studies are revolutionizing the search for the genes underlying human complex diseases. The
main decisions to be made at the design stage of these studies are the choice of the commercial genotyping chip to be
used and the numbers of case and control samples to be genotyped. The most common method of comparing different
chips is using a measure of coverage, but this fails to properly account for the effects of sample size, the genetic model of
the disease, and linkage disequilibrium between SNPs. In this paper, we argue that the statistical power to detect a
causative variant should be the major criterion in study design. Because of the complicated pattern of linkage
disequilibrium (LD) in the human genome, power cannot be calculated analytically and must instead be assessed by
simulation. We describe in detail a method of simulating case-control samples at a set of linked SNPs that replicates the
patterns of LD in human populations, and we used it to assess power for a comprehensive set of available genotyping chips.
Our results allow us to compare the performance of the chips to detect variants with different effect sizes and allele
frequencies, look at how power changes with sample size in different populations or when using multi-marker tags and
genotype imputation approaches, and how performance compares to a hypothetical chip that contains every SNP in
HapMap. A main conclusion of this study is that marked differences in genome coverage may not translate into appreciable
differences in power and that, when taking budgetary considerations into account, the most powerful design may not
always correspond to the chip with the highest coverage. We also show that genotype imputation can be used to boost the
power of many chips up to the level obtained from a hypothetical ‘‘complete’’ chip containing all the SNPs in HapMap. Our
results have been encapsulated into an R software package that allows users to design future association studies and our
methods provide a framework with which new chip sets can be evaluated.
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Introduction
The International HapMap project [1,2] documented the
strong correlations between alleles at polymorphic loci in close
physical proximity along human chromosomes. As a consequence
it is necessary to genotype only a subset of loci to capture much of
the common variation in the genome. Combined with recent
technological innovations this observation has made the concept of
genome-wide association (GWA) studies a reality [3,4]. Over the
few last years these studies have been very successful in uncovering
new disease genes for many different complex diseases [5]. Well
over 300 such loci have already been published and many more
studies are currently being planned.
In the design of such studies two fundamental decisions have to
be made: which loci to genotype, and in how many individuals.
Both decisions have practical constraints. For example it is
currently not possible to assay all known variation in the human
genome at a reasonable cost and choices must be made between a
set of commercially available genotyping chips. Similarly, sample
sizes are often limited by the number of well characterized clinical
samples. Therefore, ultimately, the researcher and funding bodies
must ask how to use the financial and practical resources available
in order to best further the understanding of the genetics of the
disease or trait of interest. A primary consideration should be the
power of the study: the probability of detecting a variant assumed
to be causal.
In comparing chips for GWA studies it has been common to ask
what proportion of SNPs not directly genotyped are ‘‘captured’’ or
‘‘tagged’’ by the chip, i.e. are well predicted, via LD, by a SNP, or
combination of SNPs, on the chip. To do so it is necessary to
define the level of prediction required, or equivalently to set a
threshold for the required level of correlation. Although arbitrary,
this has often been set at 0.8 [6,7,8]. The resulting proportion of
SNPs captured at this level is often referred to as the coverage of the
chip. Having specified the threshold it is possible to estimate the
coverage of a particular chip from HapMap data, although we
PLoS Genetics | www.plosgenetics.org 1 May 2009 | Volume 5 | Issue 5 | e1000477note that some care is required to account for SNPs not in
HapMap [8].
Here we focus instead on the power of particular chips to detect
causal variants of different effect sizes, and the way in which this
varies with study size and/or study cost and when using genotype
imputation methods. Although coverage is straightforward to
estimate, power is a complicated function of the set of SNPs on
the chip, effect size, and sample size, and can only be assessed by
simulation.
It turns out that differences in coverage between chips are often
not reflected in substantial differences in power and that the use of
genotype imputation further reduces these differences. Study
power is routinely used throughout science in experimental design
and we argue that it should be the primary consideration in
designing GWAs. This approach was used in settling several
design questions in the Wellcome Trust Case Control Consortium
[5]. Our results have been encapsulated in a user-friendly R
package that allows the power of different chip and sample size
combinations to be assessed given a total budget for the study.
Knowledge of study power is also invaluable when analysing
data from a study. Assessment of whether positive results at a
particular significance level are ‘‘real’’ or due to chance requires
knowledge of power [5], and the practical decision of how far
down the list of potential associations one should go in replication
studies should be informed by power considerations.
Other comparisons of chips have been carried out but have
either focussed exclusively on estimating coverage [8], have been
limited in scope of which chips have been evaluated [9] or have
used analytical calculations that do not properly take into account
the complex LD structure of the human genome [10,11] or failed
to assess the impact of imputation correctly [11]. A recent paper
[12] has used chip data to assess the performance of the chips but
the small sample size (N=359) means that these results cannot be
used to assess power of new study designs of more realistic sizes. In
addition, the simulations of quantitative phenotypes used the
Signal to Noise Ratio (SNR) to measure effect size of the causal
SNP which is non-standard and difficult to interpret. For binary
traits, simulations assumed a disease prevalence of 25%, a relative
risk of 3 and a sample size of only 75 cases and 75 controls. These
parameter settings are not realistic for genome-wide association
studies or useful when designing new studies.
Results
Theoretical Results
Study power depends on assumptions about the underlying
disease model, in addition to effect sizes and sample sizes. When
the true causative SNP is not on the genotyping chip there will
typically be several SNPs on the chip which are correlated with it.
One or more of these could give a signal of significant association
and hence allow detection of the locus. The LD structure of the
human genome is sufficiently complicated that this effect cannot
be captured analytically. It must be assessed via simulation studies.
Nonetheless, there is one very simple situation for which
analytical calculation is possible and helpful: that of the simplest
disease model in which only a single SNP, correlated with the
causal variant, is genotyped. For a design with the same number of
cases and controls, under the disease model in which disease risk
changes multiplicatively with the number of copies of the risk allele
carried by an individual (this model is often referred to as the
additive model because risk increases additively on the log scale),
there is a known analytical relationship [13]:
E x2   
! Nc2p(1 { p)r2, ð1Þ
where x
2 is the chi-squared test statistic, N the number of cases
and controls, c the effect size, p the allele frequency of the risk
variant and c
2 is the correlation between the marker and causal
SNP.
Although the real problem is much more complicated than this
setting, Equation 1 does provide some useful intuition. Firstly,
when the relative effect size is large (Nc2p(1{p) & 100) the
correlation between the marker and causal SNP may only need to
be weak (r
2%0.8) for the association to be detected (the expected
test statistic is big). Equally, if the relative effect size is small
(Nc2p(1{p) v 10) then even strong or complete association
(0.8,r
2#1) may not generate sufficient power to reject the null
hypothesis of no association.
Simulating Case-Control Samples – HAPGEN
Assessment by simulation of the power of a particular chip
requires simulation of large sets of case and control samples which
mimic the LD patterns in human populations (see Figure S1 for an
example). The approach we use, implemented in a software
package called HAPGEN is conceptually simple and is illustrated
in Figure 1. We have previously used this approach to compare
different analysis methods and has been briefly describe before
[14]. In this paper we provide full details of the approach and
these are given in the Methods section.
Informally, the required samples are built up from the known
haplotypes in HapMap. Consider first the simulation of control
samples in a region of the genome. A particular control individual
is simulated by separately simulating its two haplotypes in the
region. Each of these haplotypes is made up as mosaics of the
known haplotypes in HapMap, with the mechanism for construct-
ing these mosaic haplotypes based on population genetics theory.
Fine-scale estimates of recombination rates are used to calculate
the probability of breaks in the mosaic pattern as one moves along
the region.
For a given SNP assumed to be causal under a particular disease
model and effect sizes, it is straightforward to calculate the
Author Summary
Genome-wide association studies are a powerful and now
widely-used method for finding genetic variants that
increase the risk of developing particular diseases. These
studies are complex and must be planned carefully in
order to maximize the probability of finding novel
associations. The main design choices to be made relate
to sample sizes and choice of commercially available
genotyping chip and are often constrained by cost, which
can currently be as much as several million dollars. No
comprehensive comparisons of chips based on their
power for different sample sizes or for fixed study cost
are currently available. We describe in detail a method for
simulating large genome-wide association samples that
accounts for the complex correlations between SNPs due
to LD, and we used this method to assess the power of
current genotyping chips. Our results highlight the
differences between the chips under a range of plausible
scenarios, and we demonstrate how our results can be
used to design a study with a budget constraint. We also
show how genotype imputation can be used to boost the
power of each chip and that this method decreases the
differences between the chips. Our simulation method and
software for comparing power are being made available so
that future association studies can be designed in a
principled fashion.
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simulated separately by first simulating the genotype of the case at
the causative SNP and then working outwards in each direction to
construct the haplotypes carrying the alleles simulated at the
causative SNP. Loosely, this process will result in oversampling of
HapMap chromosomes which carry the risk allele, with the effect
dropping off as one moves away (in genetic distance) from the
causative locus (see Figures S2, S3, and S4 for examples).
We apply the method here to an assessment of the power of
different chips, but we note that there are many other settings
which require simulations of large case-control samples. These
include comparisons of analysis methods [14] and tagging
approaches [15], assessments of parameter estimates, and design
questions for follow-on studies such as resequencing and fine
mapping of associated regions.
The Power of GWAS Using Commercially Available Chips
We assessed the power of commercially available chips via
simulation. Each simulation assumed a particular SNP in
HapMap was causative, with a given effect size and used the
HAPGEN package to simulate case and control samples of
different sizes. In the simulated data we then restrict attention to
the genotypes at only the SNPs on the chip in question and ask
whether analysis of these would yield a significant result for any of
the SNPs on the chip. An estimate of power is obtained by
repeating the simulation over a large number of putative disease
SNPs across the genome and using the proportion of simulations
in which we find a significant test statistic.
For definiteness, in the results presented below we simulate data
under the additive disease model, and in analysis of the data
consider each SNP separately and apply the so-called trend, or
Cochran-Armitage test [16], a chi-squared test with one degree of
freedom. We fix a significance level of 5610
27, and vary the
number of cases and controls in the simulated study. There are
various other versions of these assumptions which could be made.
We explicitly look at one set of multi-marker tests below and also
carry-out a limited set of simulations to assess the impact of
genotype imputation.
Figure 1. Schematic of how power is estimated. At the top of the figure is the recombination map and haplotypes estimated from the HapMap
project [1]. Using this population genetic information we simulate a case-control sample (grey lines) where the red dots indicate the disease locus
and blue dots indicate linked genetic variation. By performing a test of association at each SNP on the genotyping chip we can estimate power by
counting the number of simulation for which a test statistic exceed a significance threshold (dotted line). We compare genotyping chips by changing
the set of SNP at which we carry out a test. See Methods.
doi:10.1371/journal.pgen.1000477.g001
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adopted regarding genome-wide association studies. One is to
regard the GWAS as a self-contained experiment in its own right
with the statistical inference being a formal hypothesis test of the
null hypothesis of no association. From this perspective, the goal at
the conclusion of the GWAS is to decide whether particular SNPs
are, or are not, associated with the phenotype of interest.
But this is not what happens in practice. There is a strong
consensus in the field that the results of association studies should
not be relied upon without additional (statistically significant)
evidence from analyses in independent replication samples [17] ,
and many major journals have policies which preclude publication
of GWAS studies by themselves, without such replication
evidence. Common practice is thus to regard the GWAS as an
experiment to highlight SNPs of interest, and then to take as many
as possible of the interesting SNPs into replication studies.
We adopt the second perspective throughout this paper, and
our power calculations are for the probability that for each of the
genotyping chips considered, there will be SNPs reaching a
prespecified, low, p-value, under specific assumptions about the
underlying genetic effects. Given current practice, we believe
the right quantity to calculate would be the probability, for the
respective chips, effect sizes, and sample sizes, that the experiment
would give rise to SNPs showing enough signal to be taken
forward for replication. This is (inevitably) ill-posed, so we focus
instead on a surrogate for it, namely the probability that at least
one SNP will have a p-value below a very stringent threshold. In
this context there is nothing special about the choice of p-value
threshold, and it is now well understood, for example from meta-
analyses, that SNPs well down any ranked list of hits from the
GWAS associations can still be genuine associations. For
definiteness, we focus throughout on the threshold of
p,5610
27). This is deliberately set so that false positive rates
will be low – for example, most SNPs with trend test p-values
passing this threshold in GWAS studies, including all of those in
the WTCCC experiment, have had associations confirmed in
replication studies (see [18] and the NHGRI Catalog of Published
Genome-Wide Association Studies at http://www.genome.gov/
GWAStudies/). Choice of a different p-value threshold changes
the numerical value of the power we calculate, but does not affect
the relative performance of the chips, or the relative effect of
sample size (data not shown).
If one were to adopt the first of the two perspectives on a GWAS
study, namely that it is a formal statistical hypothesis test in its own
right, then power comparisons become more complicated, at least
under a frequentist statistical perspective: for a given nominal per-
SNP significance level, the overall GWAS experiment will have
somewhat different false positive rates for the different commercial
chips, because they have different SNP sets, or when some SNP
genotypes are imputed, depending on the number of imputed
SNPs, for the same reason. Actually, even for a fixed chip, overall
false positive rates will differ depending on the population in which
the GWAS is conducted, because of differing patterns of LD
between the SNPs on the chip (and hence different effective
numbers of independent tests).
We do not pursue this approach here, principally because it
does not reflect the way GWAS experiments are typically used in
practice: regardless of the genotyping chip used, whether or not
genotype imputation is employed, and the population studied,
researchers tend to focus on the most significant SNPs after the
GWAS and try to confirm that they are real in replication studies.
In addition, as noted above, overall GWAS false positive rates are
low, for any of the commercial chips, at the very low per-SNP
significance level we consider. Nonetheless, in what follows,
readers should be aware that we are comparing power, defined
here as the probability that at least one SNP reaches a fixed p-
value threshold under specific assumptions about design and effect
sizes, across settings in which these very low false positive rates will
differ between chips (and across populations).
In calculating power, as thus defined, we simulate data under
the assumption that a particular allele is causal and then look to
see whether any SNPs on the respective genotyping chip, within a
large region around the causal SNP attain the specified
significance level. In ignoring the SNPs on the chip elsewhere in
the genome, this approximation will underestimate the probability
of there being a SNP meeting the significance threshold, but at the
very low threshold, the probability of there being a SNP elsewhere
in the genome meeting the threshold is extremely small, so that
effect of this approximation will be minimal and our power
calculations based on only on SNPs within the 1Mb region
containing the causal SNP will be very close to the true values.
We simulated putative disease loci at SNPs in phase II of the
HapMap within twenty-two one megabase regions on each of the
autosomes, a total of nearly 50,000 SNPs, which together are
typical for the genome in terms of SNP coverage and
recombination rates (see Figure S5 and Text S1 for details).
We investigated the power afforded by seven different
genotyping chips: the 100 k, 500 k and 6.0 chips from Affymetrix
(www.affymetrix.com) and the 300 k, 610 k, 650 k and 1 M chips
from Illumina (www.illumina.com). These chips sets differ in the
way in which the SNPs are chosen and the total number of SNPs
assayed.
As technology develops and genotyping chips become denser it
is a natural question to ask how much power would be gained by
genotyping additional SNPs or by using genotyping imputation
methods [14]. To facilitate such comparisons we evaluated the
performance of a hypothetical chip that contains all the SNPs in
HapMap to act as a point of reference in our results. The
performance of this ‘complete’ chip is shown as a solid black line in
all of the figures showing power. Since the simulations we carry
out only use HapMap SNPs as causal SNPs this analysis
approximates the scenario in which we have a chip which types
all possible SNP variation.
We return below to consideration of results for studies in the
Yoruban population. Focussing now on the power curves in the
top row of Figure 2 several features are evident. The first is the
profound effect of sample size. Effect sizes of 1.5 or smaller might
be typical of what would now be expected for most variants
affecting susceptibility to common human diseases [5]. For effect
sizes at the top of this range (1.3–1.5) very large studies (say 2,000–
3,000 cases and the same number of controls) are needed to have
reasonable power, while for smaller effect sizes even studies of
5000 cases and 5000 controls have very little power. This ties in
with growing empirical evidence. For example, for Crohn’s
disease, the WTCCC study, of 2000 cases and 3000 controls
found 9 loci with p,5610
27, whereas several smaller studies
published around the same time each found only one or two of the
loci, with little overlap across these smaller studies, consistent with
each having modest power for the larger set of loci. Further, recent
meta-analyses of 4,539 cases for type 2 diabetes and 3,230 for
Crohn’s disease have been needed to discover further loci with
estimated effect sizes in the range 1.1–1.2. Even for a disease not
previously studied by GWA, studies with fewer than 2000 cases
and 2000 controls will have low power, except in special
circumstances, for example if there are loci with larger effect sizes
than has been typical across many other diseases.
A second general feature of the power curves for Caucasian
studies in Figure 2 is that aside from the Affymetrix 100 K chip
Designing Genome-Wide Association Studies
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power across the other seven chips. For Caucasian samples the
chips are typically ordered (with decreasing power): Illumina 1M,
Illumina 650 k, Illumina 610 k, Affymetrix 6.0, Illumina 300 k,
Affymetrix 500 k, but the absolute difference in power between
the best and worst of these chips is often no more than around
10%. Put another way, for effect sizes in the range 1.3–1.5, a study
with the Affymetrix 500 K chip would have the same power as one
with the Illumina 1 M chip if its sample size were larger by 10–
20%, with smaller increases in sample sizes giving studies with
other chips the same power. Further, in Caucasian studies, power
for all chips other than the Affymetrix 100 K chip is quite close to
the best which could be obtained, namely by directly genotyping
the causative SNP.
Rare Alleles and Small Effect Sizes
Equation 1 makes clear the dependence of power on the
frequency of the risk allele. The results in Figure 2 are averaged
over putative causative SNPs with a risk allele frequency (RAF) in
the range 5–95%. Figure 3 shows that this hides quite different
behaviour depending on whether the putative disease SNP is rare
or common, and that the conclusions in the preceding subsection
apply principally for common causative SNPs. The Figure shows a
substantial difference in power for common and rare alleles with
the same effect size and that power is minimal for the rare alleles
when the effect size is small. These results refer to single-SNP
analyses. While there are definitely more powerful analysis
methods for rare alleles [14], this is not a major factor in the
loss of power, and neither is the incomplete coverage of the SNPs
on the commercially available chips: even using a sample size of
3000 cases and controls and genotyping the causal locus directly
(black line) is unlikely to lead to a test statistic which will reach the
small levels of significance thought appropriate for GWAS.
There is an open question as to whether rarer causal alleles
might have larger effect sizes than common causal alleles. If this
were though plausible, then in assessing power overall for a
particular chip, one could focus in Figure 3 on particular ranges of
effect sizes for common causative alleles and a different range of
effect sizes for rarer causative alleles.
It is becoming clear that many loci harbouring common alleles
affecting common diseases will have effect sizes in the range 1.1–
1.2, and our simulations demonstrate that there is almost no power
to detect these in studies of the size currently underway. As has
already been shown empirically [19,20] these loci can be found by
meta-analyses and follow up in larger samples of GWA findings.
Slightly larger relative risks do become detectable in large samples.
Figure 2. Plots of power (solid lines) and coverage (dotted line) for increasing sample sizes of cases and controls (x-axis). From left to
right plots are given for increasing effect sizes (relative risk per allele). Both power and coverage range from 0 to 1 and are given on the y-axis. Results
are for single-marker test of association and for simulations where the risk allele frequency of the causal allele is .0.05. The top row shows power for
case-control studies simulated in a Caucasian population based on the CEU HapMap panel. The bottom row relates to case-control studies simulated
from the YRI HapMap panel.
doi:10.1371/journal.pgen.1000477.g002
Designing Genome-Wide Association Studies
PLoS Genetics | www.plosgenetics.org 5 May 2009 | Volume 5 | Issue 5 | e1000477Designing Genome-Wide Association Studies
PLoS Genetics | www.plosgenetics.org 6 May 2009 | Volume 5 | Issue 5 | e1000477For example the power to detect an effect of size 1.3 jumps from
almost zero with 1000 cases and 1000 controls to over 50% in a
study three times the size.
Figure 3 also demonstrates that chip sets differ in the power they
offer to detect associations at different frequencies. Most
noticeably, when averaged over common alleles the Illumina
300 k chip set offers more power than Affymetrix 500 k. For rare
alleles, the opposite is true with the Affymetrix 500 k chip having
more power than the Illumina 610 k chip. This is most likely due
to the way in which the Illumina SNP sets have been designed to
specifically tag the common variation present in the HapMap
panels.
Power of Chips Compared to a ‘Complete Chip’
Immediately apparent is how close, for studies in Caucasian
populations, the genotyping chips track the power afforded by the
ideal ‘‘Complete chip’’ in a given study design and disease model.
Figure 3 illustrates that the potential benefits of increasing SNP
density on the chips or from using imputation [14] are greatest for
low frequency SNPs. When focusing on common alleles, the
potential benefits are greatest for the Affymetrix 100 k and 500 k
chips and the Illumina 300 k chip and we show this when
specifically consider imputation below (see Table 1). However, a
clear consequence of these results is that for any of the chips in
current use, increasing sample size is likely to have a bigger effect
on power than increasing SNP density.
Power versus Coverage
A striking feature of Figures 2 and 3 is that substantial
differences in coverage between different chips do not translate
into big differences in power. Put another way, coverage is often a
poor surrogate for power. As an example, the coverage in the
CEU HapMap population (r
2$0.8) provided by the Affymetrix
500 k and Illumina 610 k chips are 65% and 87% respectively, a
difference of 22%. On the other hand, the difference in power e.g.
for relative risk 1.5 and 1500 cases and controls, is only 7% (66%
and 73% respectively).
In one sense this shouldn’t be surprising. Coverage is measured
to a hard threshold: so if SNP has r
2 of 0.85 to its best proxy on
one chip and 0.75 to its best proxy on another chip, it will be
counted as ‘‘covered’’ by one chip but not by the other, whereas
the difference in power is small. Coverage statistics also do not
depend on study size or disease model.
Figure 4 illustrates the differences in correlation structure for
two chips. For each HapMap SNP we found it’s best ‘‘tag’’ (the
SNP on the chip with which it has the highest r
2) and generated a
histogram of these maximized r
2 values. To recover coverage we
simply count the proportion of SNPs for which the best tag r
2 is
$0.8, coloured red in the bottom row of figure 4. In this sense,
informally, it is useful to think of coverage as assuming that there is
power one for every ‘‘tagged’’ SNP and no power for every other
SNP. This is of course false, in ways which help to explain why
coverage differences do not translate into power differences. When
a SNP is common and the effect size is moderate or large, there
will still be good power to detect it even if the best SNP on the chip
only has r
2=0.5 or less. At the other extreme, for rare SNPs,
unless the effect size is very large, power would be low even if the
SNP had a perfect proxy on the chip. Thus even if these SNPs
were well covered by one chip and completely missed by another
they would not contribute to a difference in power between the
chips because both chips would have power close to zero for them.
The top row of Figure 4 shows the average power for SNPs in each
LD bin. For the Affymetrix 500 K chip, there is a greater
contribution to power from the sets of SNPs which are not well
‘‘covered’’, than for the Illumina chip, and hance a smaller
difference in power than in coverage.
Case-Control Population
For several reasons it is of interest to study the power of
commercially available chips in different populations. Firstly the
Illumina 100 k, 300 k and 610 k chips are aimed at capturing
variation in the CEU population, whereas the Affymetrix 500 k
chip is not designed with a specific population in mind.
Furthermore the Illimina 650 k chip has a subset of SNPs targeted
at capturing variation in the HapMap YRI (Yoruba, Africa)
population. LD will not extend as far in the YRI collection [1] as
in the CEU, reducing the coverage of a given set of SNPs.
Figures 2 and 3 show the results of power calculation using the
distribution of diversity in both the HapMap CEU and YRI
populations. The results show that the increased ancestral
recombination leads to a loss of power and coverage across all
chips for a range of study designs. The difference between the
power available from commercial genotyping chips and that
achievable by exhaustively assaying all SNPs shows that increasing
marker density may yield a better return than a similar approach
in non-African populations. The Illumina 650 k chip, with the
YRI fill-in illustrates these potential benefits, showing a marked
increase in power over the 610 k. However the performance of the
Illumina 300 k chip, designed using the CEU HapMap, falls below
Table 1. The table shows the power for each chip with a
sample size of 2000 cases and 2000 controls and a relative risk
at the causal SNP of 1.3 using a p-value threshold of 5610
27.
Chip Chip SNP Tests MultiMarker Tests IMPUTE
Affy100 k 0.178 0.212 0.242
Affy500 k 0.363 0.378 0.450
Illu300 k 0.392 0.424 0.467
Illu610 k 0.439 0.455 0.488
Illu650 k 0.443 0.458 0.492
Affy6.0 0.420 0.433 0.478
Illu1M 0.457 0.461 0.493
Complete 0.499 0.499 0.499
Three different methods of analyzing the genotype data from each chip are
shown: (a) testing just the SNPs on each chip, (b) using MultiMarker Tests in
addition to the tests at each chip SNP, and (c) carrying out imputation using
IMPUTE and testing all imputed SNPs in addition to those on each chip. The last
line of the table shows the power that woud be obtained using the ‘Complete’
chip.
doi:10.1371/journal.pgen.1000477.t001
Figure 3. Power for Common versus Rare alleles. Plots of power (solid lines) and coverage (dotted line) for increasing sample sizes of cases and
controls (x-axis). From left to right plots are given for increasing effect sizes (relative risk per allele). Both power and coverage range from 0 to 1 and
are given on the y-axis. Results are for single-marker test of association. The top two rows show the power for rare risk alleles (RAF,0.1) and the
bottom two rows show the power for common risk alleles (RAF.0.1). Rows 1 and 3 show power for case-control studies simulated in a Caucasian
population based on the CEU HapMap panel. Rows 2 and 4 relate to case-control studies simulated from the YRI HapMap panel.
doi:10.1371/journal.pgen.1000477.g003
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YRI HapMap panel.
It is not yet clear how closely patterns of diversity and LD in
other African populations mimic those in the Yoruba, and hence
to what extent the power results will translate to studies in other
populations. One general point is that the Illumina 650 k chip was
designed specifically to capture common Yoruban variation, so
one might expect power for this chip to decrease in other African
populations, for which it is not specifically designed. On the other
hand, the Affymetrix 500 k chip was not designed using this data,
so there would be not a systematic effect changing power estimates
for other African populations. As a consequence, differences in
power between the Illumina 650 k chip and Affymetrix chips may
well be smaller in other African populations.
Figure 4. Histograms of the proportion of SNPs in the 22 1Mb regions (see Methods) in HapMap Phase II for which the maximum r
2
with a SNP on the genotyping chip in in one of eleven bins (increasing in correlation (LD) from left to right). The same histograms are
coloured in two ways. The top row shows in red the percentage of the SNPs in each bin detected (See Methods and text) when selected to be the
causal SNP in our simulations (the proportion of the total volume of the bars coloured red is therefore an estimate of power). In the bottom row all r
2
bins above 0.8 are coloured red (the proportion of the total volume of all the bars is therefore an estimate of coverage). Note that the use of HapMap
data in choosing SNPs for the Illumina chip leads to a higher proportion of SNPs in high r
2 bins.
doi:10.1371/journal.pgen.1000477.g004
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Genotype Imputation
Multi-marker methods, which use combinations of SNPs, have
been suggested as an efficient way to increase both coverage and
power [15]. Figures S6 and S7 show the results of simulations that
implement the multi-marker tests. In these figures the dotted lines,
which represent coverage, are higher for all chips in comparison to
single marker approaches (Figures 2 and 3) consistent with
previous observations. We find that multi-marker approaches also
increase statistical power to detect disease loci, but that the
increase is modest relative to coverage, and the broad conclusions
above are not much affected. Interestingly, when comparing
across genotyping platforms, we find for example that the
Affymetrix 500 k chip gains more by combining SNPs than the
Illumina 300 k chip.
Genotype imputation methods [21,14] are now being widely
used in the analysis of genome-wide association studies [5] and
meta-analysis of such studies [22,20]. These methods can be
thought of as a more sophisticated version of Multi Marker tests
but are relatively much more computationally demanding. We
carried out an evaluation of the boost in power that can be gained
by imputation using the program IMPUTE [14]. For our
simulations with a sample size of 2000 cases and 2000 controls
and a relative of the causal SNP or 1.3 we ran IMPUTE on the
genotype data from each of the chips under study using the CEU
HapMap as the basis for imputation. We then carried out a test of
association at all the imputed SNPs in addition to the SNPs on
each chip. We used our program SNPTEST to carry out tests of
association at imputed SNPs to properly account for the
uncertainty that can occur at such SNPs[14]. The results of the
simulations are shown in Table 1 and shows that the use of
IMPUTE provides a noticeable boost in power over testing just
the SNPs on each chip or using Multi Marker tests (as defined in
[15]). This agrees with our previous results [14]. It is also very
noticeable that imputation reduces the differences in power
between the chips and that the use of imputation produces a level
of power that is almost as high as our hypothetical ‘complete’ chip.
We also note that the boost in power is more substantial than
that estimated in another recent study [11]. A close look at the
details of this other study shows that the only imputed SNPs used
were those (a) which had real genotype data from one of the other
chips, and (b) the imputed and real data at the SNP agreed with an
r
2.0.8. So for example, for the Affy 500 k chip only genotypes at
427,838 imputed SNPs were used, rather than all those available
from HapMap (approximately 2.5 milion SNPs), as normal
practice when carrying out imputation. Using such a filter clearly
creates a bias towards imputed SNPs that are almost perfect tags
for SNPs on the chip so it is not surprising that this study shows
such small increases in power when using imputation.
Unequal Case Control Sample Sizes
One option open to researchers who would like to increase
power in the context of limited case series is just to increase the
control collection. This strategy might include using cases for one
disease as extra controls for another (assuming suitably different
disease aetiologies and similar population history). We investigated
the utility of such an approach by performing simulations with
1000 cases and an increasing number of control (Figure S8).
Although the gains are not as strong as increasing both the case
and control sample sizes (Figure 2), the ability to reject the null
hypothesis of no association increase considerably with the size of
the control panel. For example, adding an extra 2000 controls to a
case-control study with sample size 1000–1000 increases power to
detect an effect of 1.5 typically by 20%. Subject to care in their
use, the growing availability of genotyped sets of controls promises
to make this a possibility worth investigating for many studies.
Designing a New Study
The results of our simulations can be used to assess the power of
a range of possible designs for a given budget and have been
encapsulated in a user friendly R package for this purpose (see
Software section). Table 2 shows the study size and power that can
be achieved on a budget of $2,000,000 for each of the chips
assuming the disease causing allele of has a relative risk of 1.5, a
risk allele frequency of at least 0.05 and that a p-value threshold of
5610
27 is used to define power. Since the different chips vary in
their prices and their per sample processing costs we obtained
quotes from service providers for the various chips and averaged
them (see Text S1). The prices were based on quotes for 4000
chips and quotes were converted to US dollars using current
exchange rates where necessary. We obtained 5 different quotes
for the Affymetrix chips and 6 different quotes for the Illumina
chips.
The results show that in this scenario the Illumina 300 k chip
produces the most powerful design (82.1%) primarily due to its
relatively cheap price compared to the other chips. Using the same
sample size (2653 cases and controls) the ‘Complete’ chip has a
power of 88.1%. It is also notable that the power of thie Illumina
300 k chip is nearly 17% greater than the power that can be
achieved by the Illumina1 M chip (63.5%) which has approx-
imately 3 times the SNP density. These result further illustrate the
deficiencies in using coverage as a measure of chip performance as
sample size is not factored into the calculation. Although these
results are interesting we advise against using them directly in the
design of a new study. There were noticeable variations in the
quotes we obtained from the service providers and prices are likely
to change through time. We encourage new studies to re-calculate
power of various designs based on a set of up to date and
competitive prices and to take into account the general effect that
genotype imputation can have on these power estimates.
Discussion
Because of the complexity of human LD patterns, many
questions of interest cannot be addressed analytically. We have
described in detail our simulation method, HAPGEN, for
generating large samples of case and control data at every
Table 2. The table shows the power that can be achieved by
each chip with a total budget of $2,000,000.
Chip Average Price ($) Number of cases/controls Power
Affy500 k 420 2381 0.767
Illu300 k 377 2653 0.821
Illu610 k 452 2212 0.818
Affy6.0 505 1980 0.772
Illu1M 750 1257 0.635
Complete - 2653 0.881
These results were calculated assuming a disease causing allele with a relative
risk of 1.5, a minor allele frequency of at least 0.05, that a p-value threshold of
5610
27 is used to define power and that the study should consist of an equal
number of cases and controls. The second column shows the prices that we
were able to obtain for these products at the time of submission. The last line of
the table shows the power that woud be obtained using the ‘Complete’ chip
using the sample size equal to that of the most powerful design.
doi:10.1371/journal.pgen.1000477.t002
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present in the HapMap data. The software can simulate case data
under a single causal disease SNP model for specified genotypic
relative risks. We have used the method here to assess the power of
various commercially available genotyping chips for case-control
genome-wide association studies, but note that it could be utilised
to assess other design questions, in the evaluation of analytical
methods, and in considering follow-on studies such as resequen-
cing and fine-mapping.
In Caucasian populations the differences in power afforded by
current-generation genotyping chips are not large, and the power
of these chips is close to that of an optimal chip which always
directly genotyped the causal SNP. Listed in order of decreasing
power for the CEU population, averaged over all potential disease
SNPs with RAF $5%, the chips we considered were: Illumina
1M, Illumina 650 k, Illumina 610 k, Affymetrix 6.0, Illumina
300 k, Affymetrix 500 k and Affymetrix 100 k. In line with our
previous work we have shown that imputation can boost the power
of each chip substantially and that the resulting power will
approach that which could be obtained by a hypothetical
‘complete’ chip that types all the SNPs in HapMap.
One limitation of the approach we (and others [9,10,12,11])
have used is that the causal SNP is assumed to be one of those
SNPs in the HapMap panel and this will not always be true. Other
studies [1] have shown that the majority of SNPs not in HapMap
will be highly correlated with the SNPs that are in HapMap and
this is especially true for the more common SNPs. This means
there is a slight bias in our power results for each chip and for the
use of imputation but we do not expect it to be large. A
consequence of this point is that the power we estimate for the
‘complete’ chip approximates the power we might obtain if we had
a chip which typed all the SNPs that exist in the human genome.
A main conclusion from our analysis is that study size is a
crucial determinant of the power to detect a causal variant.
Increasing study size typically has a larger effect on power than
increasing the number or coverage of SNPs on the chip, at least
amongst chips currently available. Even for effect sizes at the
larger end of those estimated to date for common human diseases
(RRs of 1.3–1.5) quite large sample sizes, at least 2000 cases and
2000 controls and ideally more, are needed to give good power to
detect the causal variant. When case numbers are limited, there
are still non-trivial gains in power available from increasing just
the number of controls. Care is needed in assessing the
appropriateness of a set of controls, but as larger sets of control
genotypes are made publicly available this strategy has consider-
able appeal, whatever the number of available cases. SNPs with
smaller effect sizes are unlikely to be detected even in studies of the
sizes currently undertaken, but as has been shown empirically for
several diseases, these can be found by meta-analyses which
combine different GWAs, or by follow-up in large samples of SNPs
which look promising in the original GWA but fail to meet the low
levels of significance thought appropriate for GWAS.
When the causal SNP is rare (MAF,10%), all chips have low
power unless its effect is large and sample sizes are large. This
conclusion would hold even if the chip directly genotyped the
causal SNP. The relative ordering of different chips, on the basis of
power, also changes in this context.
As would be expected, power is also lower for all chips for
samples which match the patterns of LD seen in the Yoruba
HapMap sample, and again the relative ordering of chips changes
in this setting. It is not yet clear how well the results for the Yoruba
would extend to other African populations.
An often-quoted metric in assessing chips is the coverage of each
chip: an estimate of the proportion of SNPs which have r
2.0.8
with at least one SNP on the chip. Although relatively simple to
calculate (and even simpler to miscalculate), not least because it
does not depend on study size, our results show that coverage can
be a poor surrogate for power, and that relatively large differences
between chips in coverage do not translate to large differences in
power.
The sets of SNPs on Illumina chips are chosen in part to
maximize particular criteria, such as coverage, for certain
populations, typically those in HapMap. One difficulty of analyses
such as those in this paper is that these resources are also the
natural ones with which to assess properties of the chips. Thus
when Illumina chips ‘‘tuned’’ to one population (say the 610 K
chip for CEU) are used in other populations, power might be
systematically lower than the levels assessed here. In contrast, SNP
sets of Affymetrix chips are chosen largely in a non-population
specific way. While power is likely to vary in populations other
than those we have considered here, there is not the same
systematic effect which would lead to a decrease in power. A
quantitative assessment of this phenomena will be possible when
dense genotype data is available for other populations, such
HapMap Phase 3.
We have assumed here that accurate genotypes are available for
all SNPs on each chip. In practice some SNPs on each chip will fail
QC tests and not be available for analyses. As a consequence, our
study will overestimate power, though this effect is unlikely to be
large. We are only able to use SNPs in HapMap as potential
disease SNPs. These may not be systematically representative of all
potential disease SNPs. HapMap SNPs have systematically higher
MAFs than do arbitrary SNPs [2], but for SNPs within a particular
range of MAF, it seems unlikely that their LD properties will differ
systematically, so, for example, we would expect our results for
common SNPs to extend beyond those in HapMap.
We have focussed on the most common GWA design, namely of
a single-stage study, and the simplest disease model. The flexibility
of the simulation approach allows many other practical aspects of
study design to be incorporated into power calculations. These
include more complex disease models, two-stage strategies (the
starting point for our work was a comparison of power for one-
and two-stage designs in the context of the WTCCC study [5]),
genotyping errors, QC filters, misidentification of cases as controls
and simple types of population structure. The HAPGEN software
also provides a useful tool for the development and comparison of
more sophisticated multi-marker approaches to detecting disease
association (e.g. imputation [14]). We therefore believe that
simulations are an essential tool in the design of association
studies by allowing a focus on study power and an assessment of
the affect on power of following a given study design. We hope
that this method will continue to find use and can be extended to
new catalogs of genetic variation such as the 1000 Genomes
Project http://www.1000genomes.org/.
As in other areas of science, power seems a central consideration
in study design and choice of genotyping chip. But other issues
may also play a role. These include coverage of particular genes,
or genomic regions of interest; the utility of GWA data for
directing downstream studies such as resequencing and fine
mapping; data quality for particular chips; and the extent to which
a chip reliably assays other forms of genetic variation such as copy
number polymorphisms. Adding data to existing studies is
straightforward if the same chip is used, but the success of
imputation methods, in particular in meta-analyses [19,20] means
that this is not essential.
In general, Affymetrix chips have more redundancy than do
Illumina chips, in the sense of containing sets of SNPs which are
correlated with each other. The immediate consequence of this is
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but there can be advantages to this redundancy: loss of a particular
SNP to QC filters may not be as costly; and signals of association
are likely to include more SNPs, thus making them easier to
distinguish from genotyping artefacts.
Ultimately power can only be calculated under an alternative
model. Thus on a practical level the optimal choice of assays and
sample sizes will actually depend on the researcher’s belief
regarding the unknown distribution of effect sizes and models
relating genotype and phenotype. In particular we show that one
might adopt different strategies depending on the expected
frequency of disease causing variant, the effect size and even the
population from which cases and controls are sampled (Figure 3).
In the continuing search to better understand the genetic basis
of common human diseases, numerous study designs can be
adopted which may involve combining data sets, imputing missing
SNPs [14], distilling signals of association over multiple experi-
mental stages, and so on. In this complex setting study power will
remain a central criterion in study design, and the kinds of
approaches developed here will continue to allow informed
decision making by experimenters.
Methods
HAPGEN
We adopt the model introduced by [23] (denoted LS from now
on), who described a new model for linkage disequilibrium, which
enjoys many of the advantages of coalescent-based methods (e.g. it
directly relates LD patterns to the underlying recombination rate)
while remaining computationally tractable for huge genomic
regions, up to entire chromosomes. Their model relates the
distribution of sampled haplotypes to the underlying recombina-
tion rate, by exploiting the identity
Pr(h1,...,hnjr)~Pr(h1jr)Pr(h2jh1;r)...Pr(hnjh1,...,hn;r) ð2Þ
where h1,…,hn denote the n sampled haplotypes, and r denotes the
recombination parameter (which may be a vector of parameters if
the recombination rate is allowed to vary along the region). This
identity expresses the unknown probability distribution on the left
as a product of conditional distributions on the right. LS substitute
an approximation for these conditional distributions (^ p p) into the
right hand side of (3), to obtain an approximation to the
distribution of the haplotypes h given r
Pr(h1,...,hnjr) & ^ p p(h1jr)^ p p(h2jh1;r)...^ p p(hnjh1,...,hn;r) ð3Þ
If h1,…,hn are n sampled haplotypes typed at S bi-allelic loci (SNPs)
LS modelled the distribution of the first haplotype as independent
of r, i.e. all 2
S possible haplotypes are equally likely, so
^ p p(h1) ~ (1=2)
S. For the conditional distribution of hk+1 given
h1,…,hk, LS modelled hk+1 as an imperfect mosaic of h1,…,hk
through the use of a Hidden Markov Model (HMM). That is, at
each SNP, hk+1 is a (possibly imperfect) copy of one of h1,…,hk at
that position where where the transition rates between the hidden
copying states are parameterized in terms of the underlying
recombination rate. The transition rates are different for each of
the conditional distributions in such a way so as to mimic the
property that as we condition on an increasingly larger number of
haplotypes we expect to see fewer novel recombinant haplotypes.
A parameterisation for the mutation rate (or emission probabilities
of the HMM) is used that has similar properties (see [23] for more
details).
The simulation of a new set of haplotypes for NU control and
NA case individuals is proceeds using the following algorithm.
1. Pick a locus from the set of markers in the real dataset as
the disease locus. The disease locus is chosen at random from all
those loci with a minor allele frequency (MAF) within some
specified range [l,u]. We use d[f1,...,Sg to denote the disease
locus, a and A to denote the major and minor alleles at the disease
locus and use p denote the sample minor allele frequency at this
locus.
2. For a given disease model simulate the alleles at the disease
locus of the new individual conditional upon case-control status.
At the disease locus we use a general genotype model in which the
frequencies of the genotypes aa, Aa and AA in control individuals
are given by (12p)
2,2 p(12p) and p
2 respectively. This assumes that
the control individuals are so-called population controls (as used
by the WTCCC study [5]) rather than individuals who have been
selected to specifically not have the disease. For case individuals
the genotype frequencies are determined by specification of the
two relative risks
a~
p(DjAa)
p(Djaa)
b~
p(DjAA)
p(Djaa)
ð4Þ
where p(Djg) denotes the probability that an individual is a case
conditional upon having genotype g. Under this model
p(aajD) ~
(1{p)
2
c
p(AajD) ~
2ap(1{p)
c
p(AAjD) ~
bp2
c
ð5Þ
where c=(12p)
2+2ap(12p)+bp
2. As an example, if p=0.1, a=2
and b=4 the control and case genotype frequencies are (0.81,
0.18, 0.01) and (0.67, 0.30, 0.03) respectively.
Assuming we have a set of k known haplotypes, the generation
of a case (control) starts by simulating a genotype g using the case
(control) genotype frequencies. This simulated genotype specifies
the alleles on the the two haplotypes of the new individual at
the disease locus. For example, if g=Aa then hk+1,d=1 and
hk+2,d=0.
3. This step involves the simulation of two new haplotypes for
the individual conditional upon the alleles simulated at the disease
locus in Step 2 and conditional upon the fine-scale recombi-
nation map across the region. This involves simulating the rest of
hk+1 and hk+2. We only describe the generation of sites right
flanking of the disease locus as the generation of the left
flanking markers is virtually identical. Also the simulation of hk+2
follows directly from our description of how the rest of hk+1 is
simulated.
Let Xj be the hidden state of the HMM that denotes which
haplotype hk+1 copies at site j (so that Xj[f1,...,kg). This state
variable is initialized at the disease locus as follows
Pr(Xd~x)~
(1{(1=2)  h h=(kz  h h)) if hx,d~hkz1,d
(1=2)  h h=(kz  h h) otherwise
(
ð6Þ
The value of   h h , as with LS, is Watterson’s point estimate
(Watterson, 1975)
  h h~(
X L{1
m~1
1
m
)
{1 ð7Þ
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the following transition rule
Pr(Xjz1 ~ x’jXj ~ x) ~
e{rjzj=k z (1 { e{rjzj=k)=k if x’ ~ x
(1 { e{rjzj=k)=k otherwise
(
ð8Þ
where zj is the physical distance between markers j and j+1
(assumed known); and rj~4Ncj , where N is the effective (diploid)
population size, and cj is the average rate of crossover per unit
physical distance, per meiosis, between sites j and j+1 (so that cjzj is
the genetic distance between sites j and j+1). This transition matrix
captures the idea that, if sites j and j+1 are a small genetic distance
apart (i.e. cjzj is small) then they are highly likely to copy the same
chromosome (i.e. Xj+1=Xj).
To mimic the effects of mutation the copying process may be
imperfect: with probability k/(k+h) the copy is exact, while with
probability h/(k+h) a mutation will be applied to the copied
haplotype. Specifically,
Pr(hkz1,j~fjXj~x,h1,...,hk)~
(1{  h h=2(kz  h h)) if hx,j~f
  h h=2(kz  h h)i f hx,j=f
(
4. Return to step 2 to generate another individual or terminate.
Illustrations of the HAPGEN method in practice and details of
the testing the method against coalecent simulations are given in
Text S1.
Details of SNP Sets Used in the Study
We used release 21 of the HapMap data for which phased
haplotypes are available in NCBI b35 coordinates. The SNPs that
occur on each genotyping chip were obtained from the websites of
Affymetrix and Illumina respectively. Some of the SNPs in these
sets do not occur in the HapMap phased haplotype data due to
QC measures applied to the raw genotype data. For the
Affymetrix 6.0 and Illumina 1 M chips 90.8% and 88.1% of the
SNPs on these chips respectively are in this release in HapMap.
This will have the effect of making our estimates of power slight
underestimates of the true power.
We simulated data for twenty-two one megabase regions chosen
at random, one from each autosome. To ensure that the regions
used to approximate genome-wide power were representative of
the genome at large we their SNP density. Figure S5 plots the
distribution of inter-SNP distances within the 22 analysis regions
and across the whole genome for three of the genotyping chips
analyzed. The close match between the distribution, both on the
physical scale and in terms of genetic distance suggests that our
results are insensitive to the regions we chose to simulate, and can
be used to make comparisons of genotyping chips genome-wide.
Calculating Coverage and Testing for Association
We used data from the HapMap project Phase II to estimate
coverage. Single marker coverage was defined to be the proportion
of all variation (with minor allele frequency greater than 5%) in r
2
with a SNP on the genotyping chip above 0.8. Using this definition
we achieved very similar estimates to previous studies which used
the whole genome (we use twenty two representative megabases).
Multi-marker coverage was calculated by an aggressive search of
all 2-SNP and 3 SNP haplotypes within 250kb of the SNP being
tagged [6]. The SNP was tagged if any of these multi-marker tags
had r
2 above 0.8, the rule defining the haplotype was also stored
and added to the list of multi-marker tests.
Single marker tests (Cochran-Armitage test) were performed at
each SNP on the genotyping chip where information were
simulated from the relevant HapMap panel. Multi-marker tests
of association were performed in an identical fashion with the
marker being formed by the multi-marker haplotypes known to
tag HapMap variation. To avoid over estimation of power, multi-
marker tags chosen to tag the current putative disease SNP in the
simulations were excluded from the test set. Tests at imputed SNPs
took account of the uncertainty in genotypes through a missing
data likelihood as described in [14].
Software
The HAPGEN software is freely available for academic use
from the website http://www.stats.ox.ac.uk/,marchini/software/
gwas/gwas.html.
In addition, the results of the power calculations for the 7
commercially available genotyping chips have been included in an
R package called GWASpower available from http://www.stats.
ox.ac.uk/,marchini/#software.
This package allows the user to determine the most powerful
study design for a given budget. As new commercial genotyping
chips become available we will update the package to include
results of new chips. The package works by fitting a Generalised
Linear Model to the results of the simulation study and using the
model fit to predict the power for a given number of cases and
controls.
Supporting Information
Figure S1 Top plot : Linkage disequilibrium plots across the
region : D9 (top left), r
2 (bottom right). Bottom plot : Fine scale
recombination map r across the region.
Found at: doi:10.1371/journal.pgen.1000477.s001 (0.21 MB TIF)
Figure S2 For simulated dataset A (a=1.3, b=1.69) the top
plot shows D9 and r
2 LD measures. The bottom plot shows the x
2
statistic for association across the region. The vertical blue line
shows the location of the disease locus.
Found at: doi:10.1371/journal.pgen.1000477.s002 (0.28 MB TIF)
Figure S3 For simulated dataset B (a=1.5, b=2.25) the top plot
shows D9 and r
2 LD measures. The bottom plot shows the x
2
statistic for association across the region. The vertical blue line
shows the location of the disease locus.
Found at: doi:10.1371/journal.pgen.1000477.s003 (0.29 MB TIF)
Figure S4 For simulated dataset (a=1.7, b=2.89) the top plot
shows D9 and r
2 LD measures. The bottom plot shows the x
2
statistic for association across the region. The vertical blue line
shows the location of the disease locus.
Found at: doi:10.1371/journal.pgen.1000477.s004 (0.30 MB TIF)
Figure S5 Representativeness of the 22 1Mb regions used in the
simulation study. Bar plots are shown of the proportion of SNPs
which fall into increasing inter-SNP distances for three of the
genotyping chips used in this study. These distribution are
measured on the physical scale (left column) and genetic map
(right column).
Found at: doi:10.1371/journal.pgen.1000477.s005 (1.37 MB EPS)
Figure S6 Power of Multi-marker tests. Plots of power (solid
lines) and coverage (dotted line) for increasing sample sizes of cases
and controls (x-axis). From left to right plots are given for
increasing effect sizes (relative risk per allele). Both power and
coverage range from 0 to 1 and are given on the y-axis. The results
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causal allele is .0.05. The top row shows power for case-control
studies simulated in a Caucasian population based on the CEU
HapMap panel. The bottom row relates to case-control studies
simulated from the YRI HapMap panel.
Found at: doi:10.1371/journal.pgen.1000477.s006 (1.71 MB EPS)
Figure S7 Power of Multi-marker tests for common versus rare
alleles. Plots of power (solid lines) and coverage (dotted line) for
increasing sample sizes of cases and controls (x-axis). From left to
right plots are given for increasing effect sizes (relative risk per
allele). Both power and coverage range from 0 to 1 and are given
on the y-axis. Results are for single-marker test of association. The
top two rows show the power for rare risk alleles (RAF,0.1) and
the bottom two rows show the power for common risk alleles
(RAF.0.1). Rows 1 and 3 show power for case-control studies
simulated in a Caucasian population based on the CEU HapMap
panel. Rows 2 and 4 relate to case-control studies simulated from
the YRI HapMap panel.
Found at: doi:10.1371/journal.pgen.1000477.s007 (2.90 MB EPS)
Figure S8 Plots of power (solid lines) and coverage (dotted line)
for increasing sample sizes of controls (x-axis). The number of case
individuals is fixed at 1000. From left to right plots are given for
increasing effect sizes (relative risk per allele). Both power and
coverage range from 0 to 1 and are given on the y-axis. Results are
for single-marker test of association and for simulations where the
minor allele frequency of the causal allele is .0.05. The top row
shows power for case-control studies simulated in a Caucasian
population based on the CEU HapMap panel. The bottom row
relates to case-control studies simulated from the YRI HapMap
panel.
Found at: doi:10.1371/journal.pgen.1000477.s008 (1.73 MB EPS)
Text S1 Supplementary text associated with the main article.
Found at: doi:10.1371/journal.pgen.1000477.s009 (0.06 MB PDF)
Acknowledgments
We would like to thank Dr Rory Bowden for his help and advice in
comparing the different genotyping chips. This research was supported by
funding and grants from the Wellcome Trust (PD and CS), a Wolfson-
Royal Society Merit Award (PD) and the EPSRC (ZS).
Author Contributions
Conceived and designed the experiments: CCAS PD JM. Performed the
experiments: CCAS ZS. Contributed reagents/materials/analysis tools: ZS
JM. Wrote the paper: PD JM.
References
1. The International HapMap Consortium (2005) A Haplotype Map of the Human
Genome. Nature 437: 1299–320.
2. The International HapMap Consortium (2007) A second generation human
haplotype map of over 3.1 million SNPs. Nature 449: 851–861.
3. Risch N, Merikangas K (1996) The future of genetic studies of complex human
diseases. Science 273: 1516–7.
4. Hirschhorn JN, Daly MJ (2005) Genome-wide association studies for common
diseases and complex traits. Nat Rev Genet 6: 95–108.
5. The Wellcome Trust Case-Control Consortium (2007) Genome-wide associa-
tion study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447: 661–678.
6. Pe’er I, de Bakker PI, Maller J, Yelensky R, Altshuler D, et al. (2006) Evaluating
and improving power in whole-genome association studies using fixed marker
sets. Nat Genet 38: 663–7.
7. de Bakker PI, Burtt NP, Graham RR, Guiducci C, Yelensky R, et al. (2006)
Transferability of tag snps in genetic association studies in multiple populations.
Nat Genet 38: 1298–303.
8. Barrett JC, Cardon LR (2006) Evaluating coverage of genome-wide association
studies. Nat Genet 38: 659–62.
9. Eberle M, Ng P, Kuhn K, Zhou L, Peiffer D, et al. (2007) Power to detect risk
alleles using genome-wide tag SNP panels. PLoS Genet 3: 1827–1837.
10. Li C, Li M, Long J, Cai Q, Zheng W (2008) Evaluating cost efficiency of SNP
chips in genome-wide association studies. Genet Epidemiol 32: 387–395.
11. Anderson C, Pettersson F, Barrett J, Zhuang J, Ragoussis J, et al. (2008)
Evaluating the effects of imputation on the power, coverage, and cost efficiency
of genome-wide SNP platforms. Am J Hum Genet 83: 112–119.
12. Hao K, Schadt E, Storey J (2008) Calibrating the performance of SNP arrays for
whole-genome association studies. PLoS Genet 4: e1000109.
13. Chapman JM, Cooper JD, Todd JA, Clayton DG (2003) Detecting disease
associations due to linkage disequilibrium using haplotype tags: a class of tests
and the determinants of statistical power. Hum Hered 56: 18–31.
14. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint
method for genome-wide association studies by imputation of genotypes. Nat
Genet 39: 906–913.
15. de Bakker P, Yelensky R, Pe’er I, Gabriel S, Daly M, et al. (2005) Efficiency and
power in genetic association studies. Nat Genet 37: 1217–1223.
16. Clayton D (2001) Population Association. In: D Balding MB, Cannings C, eds.
Handbook of Statistical Genetics. Wiley: Chichester, chapter 19.
17. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, et al. (2007)
Replicating genotype-phenotype associations. Nature 447: 655–660.
18. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into
the genetics of common disease. J Clin Invest 118: 1590–1605.
19. Zeggini E, Scott L, Saxena R, Voight B, Marchini J, et al. (2008) Meta-analysis
of genome-wide association data and large-scale replication identifies additional
susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.
20. Barrett J, Hansoul S, Nicolae D, Cho J, Duerr R, et al. (2008) Genome-wide
association defines more than 30 distinct susceptibility loci for Crohn’s disease.
Nat Genet 40: 955–962.
21. Scheet P, Stephens M (2006) A fast and flexible statistical model for large-scale
population genotype data: applications to inferring missing genotypes and
haplotypic phase. Am J Hum Genet 78: 629–644.
22. Zeggini E, Scott L, Saxena R, Voight B, Marchini J, et al. (2008) Meta-analysis
of genome-wide association data and large-scale replication identifies additional
susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.
23. Li N, Stephens M (2003) Modeling linkage disequilibrium and identifying
recombination hotspots using single-nucleotide polymorphism data. Genetics
165: 2213–33.
Designing Genome-Wide Association Studies
PLoS Genetics | www.plosgenetics.org 13 May 2009 | Volume 5 | Issue 5 | e1000477